I'm more inclined to be challenged by Nada's sentiment that it may require MNKD's ability to educate the public about the superiority label of the product as opposed to doctors' recommending it on behalf of the potential FDA superiority label. If doctors are obliged to prescibe on the basis of pharmaceutical obligations as opposed to a documented, proven alternative superiority product - this will produce more of an uphill climb than I'm currently anticipating.